Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Tebboune: Achieving economic integration must not remain a dream.
Algerian Foreign Minister Ahmed Attaf delivers a speech on behalf of Algerian President Abdelmadjid Tebboune at the Fifth Arab Development, Economic, and Social Summit in Baghdad.
Mustafa: We reaffirm our commitment to work with our brothers and friends around the world for stability and an end to wars.
Palestinian Prime Minister Mohammad Mustafa: We stress the importance of reaching an agreement to implement the initiatives of the Development, Economic, and Social Summit.
Aboul Gheit: The global economy is going through a period of turbulence.
Aboul Gheit: Concrete solutions must be found for the issue of Arab food security in line with the strategy proposed at the Arab Summit in Baghdad.
Aboul Gheit: Arab national security is an integrated whole that cannot be achieved without food, social, cyber, and other forms of security.
Arab League Secretary-General Ahmed Aboul Gheit: We present a comprehensive Arab strategy for food security at the Arab Development Summit.
The closing statement of the Arab Summit: We reaffirm our absolute rejection of the displacement of the Palestinian people and call for the delivery of aid to the Gaza Strip.
The closing statement of the Arab Summit: The goal of the Arab Summit is to unify our efforts and achieve the interests of the peoples of our region.

Experimental drug trial makes cancer disappear

  • By Al Mayadeen English
  • Source: Agencies
  • 8 Jun 2022 15:18
  • 1 Shares
4 Min Read

A modest clinical trial at Memorial Sloan Kettering Cancer Center reveals that every single rectal cancer patient who got an investigational immunotherapy treatment went into remission.

  • x
  • Experimental drug trial makes cancer disapear
    Four people were part of the successful treatment. (Memorial Sloan)

A modest clinical trial at Memorial Sloan Kettering Cancer Center discovered that every single rectal cancer patient who got an investigational immunotherapy treatment went into remission.

When the findings came in, one participant, Sascha Roth, was planning to go to Manhattan for weeks of radiation therapy, according to Memorial Sloan Kettering. That's when physicians informed her that she was cancer-free.

Read more: Researches using 'bugs as drugs' for breast, prostate cancer

Roth told The New York Times that her family wouldn't believe the news when she told them. 

To date, 14 people have seen the same astounding results. The report was published in the New England Journal of Medicine on Sunday. All of the patients had locally advanced rectal cancer and an uncommon mutation known as mismatch repair deficiency (MMRd).

They were given six months of treatment with dostarlimab, an immunotherapy medicine developed by GlaxoSmithKline, which also helped fund the research. The cancer was gone in all of them — undetected by physical exam, endoscopy, PET scans, or MRI scans, according to the researchers.

The $11,000 per dose drug was given to each patient every 3 weeks for a total of six months. It works by exposing cancer cells to the immune system, allowing it to recognize and eliminate them.

CBS News medical contributor Dr. David Agus explained that the new treatment is a type of "immunotherapy, a treatment that blocks the 'don't eat me' signal on cancer cells enabling the immune system to eliminate them."

"The treatment targets a subtype of rectal cancer that has the DNA repair system not working. When this system isn't working there are more errors in proteins and the immune system recognizes these and kills the cancer cells."

Related News

Senate report reveals Trump slashed cancer research by 31%

Type-2 diabetes linked to higher pancreatic, liver cancer risk: Study

After 6 months or more, patients continued to have no signs of cancer - without the need for the standard treatments of surgery, radiation, and chemotherapy.

Cancer has not returned to any of the patients, and they have remained cancer free for nearly 25 months after the trial came to an end. 

According to Agus, it is "amazing" and almost unheard of to have such results, adding that this "speaks to the role of personalized medicine — that is identifying a subtype of cancer for a particular treatment, rather than treating all cancers the same."

Another unexpected finding from the trial was that none of the individuals experienced major adverse effects.

In an MSK news release, Dr. Andrea Cercek, a medical oncologist and principal investigator in the study, described how usual side effects of radiation and surgery may include fertility, sexual health, and bowel and bladder function, noting that "the implications for quality of life are substantial, especially in those where standard treatment would impact childbearing potential. As the incidence of rectal cancer is rising in young adults, this approach can have a major impact."

Cercek said it was extremely rewarding to receive emails from patients that are reporting keeping all their normal body functions.

Researchers believe that the experiment should now be duplicated in much larger research, and they point out that the current study only included patients with a rare genetic signature in their tumors. However, they believe that witnessing full remission in 100% of people examined is a highly positive early indication.

Dr. Hanna K. Sanoff of the University of North Carolina's Lineberger Comprehensive Cancer Center, who was not involved in the study, believes it is unclear whether the patients were cured.

In an editorial, she wrote, "Very little is known about the duration of time needed to find out whether a clinical complete response to dostarlimab equates to cure" but did note that the preliminary results are a cause "for great optimism."

The trial is intended to involve roughly 30 individuals, providing a more complete picture of how safe and effective dostarlimab is in this population.

According to research co-leader Dr. Luis Diaz Jr., director of MSK's division of solid tumor oncology, "While longer follow-up is needed to assess response duration, this is practice-changing for patients with MMRd locally advanced rectal cancer."

  • Cancer
  • Cancer patients
  • cancer treatment

Most Read

Two F-35 jets arrive at it's new operational base Wednesday, Sept. 2, 2015, at Hill Air Force Base, in northern Utah. (AP)

F-35 near-misses over Yemen signal new risks for 'Israel': Forbes

  • Politics
  • 14 May 2025
Palestinians pray over bodies of people killed in the Israeli bombardment who were brought from the Shifa hospital before burying them in a mass grave in the town of Khan Younis, southern Gaza Strip, Wednesday, Nov. 22, 2023. (AP )

Gaza casualty figures mask a much bigger horror, new study shows

  • Politics
  • 11 May 2025
Abu Obaida

Abu Obeida posts shortly after Israeli reports about his assassination

  • Palestine
  • 15 May 2025
Gaza and the logic of necropolitics: Sovereignty measured by killing

Gaza and the logic of necropolitics: Sovereignty measured by killing

  • Politics
  • 15 May 2025

Coverage

All
Gaza prevails against genocide

Read Next

All
A Microsoft sign and logo are pictured at the company's headquarters, Friday, April 4, 2025, in Redmond, Wash. (AP)
Technology

Microsoft admits supplying AI to 'Israel' amid Gaza carnage

Israeli occupation’s tanks parked in a staging area near the border with Gaza, Friday, May 16, 2025. (AP)
Politics

'Israel' launches multi-axis assault in Gaza under 'Gideon’s Chariots'

People stand at the train ticket counter of NJ Transit at Penn Station, amid a strike by New Jersey Transit train engineers, in New York, Friday, May 16, 2025. (AP)
Economy

Commuters stranded amid first New Jersey railway strike in 40 years

Trump's tax bill stalls as Republican opposition demands deeper cuts
US & Canada

Trump's tax bill stalls as Republican opposition demands deeper cuts

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS